[Congressional Bills 118th Congress]
[From the U.S. Government Publishing Office]
[H.R. 4007 Introduced in House (IH)]

<DOC>






118th CONGRESS
  1st Session
                                H. R. 4007

   To ensure references to opioid overdose reversal agents in grant 
programs of the Department of Health and Human Services are not limited 
                              to naloxone.


_______________________________________________________________________


                    IN THE HOUSE OF REPRESENTATIVES

                             June 12, 2023

  Mr. Armstrong (for himself and Mr. Tonko) introduced the following 
    bill; which was referred to the Committee on Energy and Commerce

_______________________________________________________________________

                                 A BILL


 
   To ensure references to opioid overdose reversal agents in grant 
programs of the Department of Health and Human Services are not limited 
                              to naloxone.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Halting the Epidemic of Addiction 
and Loss Act of 2023'' or the ``HEAL Act of 2023''.

SEC. 2. REFERENCES TO OPIOID OVERDOSE REVERSAL AGENTS IN HHS GRANT 
              PROGRAMS.

    (a) In General.--The Secretary of Health and Human Services shall 
ensure that, whenever the Department of Health and Human Services 
issues a regulation, guidance, or other document for any grant program 
addressing opioid misuse and use disorders, any reference to an opioid 
overdose reversal agent (such as a reference to naloxone) is inclusive 
of any opioid overdose reversal agent that has been approved or 
otherwise authorized for use by the Food and Drug Administration.
    (b) Existing References.--
            (1) Update.--Not later than the end of calendar year 2023, 
        the Secretary of Health and Human Services shall update all 
        references described in paragraph (2) to be inclusive of any 
        opioid overdose reversal agent that has been approved or 
        otherwise authorized for use by the Food and Drug 
        Administration.
            (2) References.--A reference described in this paragraph is 
        any reference to an opioid overdose reversal agent (such as 
        naloxone) in any regulation, guidance, or other document of the 
        Department of Health and Human Services that--
                    (A) was issued before the date of enactment of this 
                Act; and
                    (B) is for--
                            (i) the grant program for State and Tribal 
                        response to opioid use disorders under section 
                        1003 of the 21st Century Cures Act (42 U.S.C. 
                        290ee-3 note; commonly referred to as ``State 
                        Opioid Response Grants'' and ``Tribal Opioid 
                        Response Grants''); or
                            (ii) the grant program for priority 
                        substance use disorder prevention needs of 
                        regional and national significance under 
                        section 516 of the Public Health Service Act 
                        (42 U.S.C. 290bb-22).
                                 <all>